Dapagliflozin Tablet, Film Coated
Product Images NDC 0781-5985

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 0781-5985). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

10mgx30tablets (10 mgx30tablets)

10mgx30tablets (10 mgx30tablets)
This is a description for a medication containing 10 mg of dapagliflozin per film-coated tablet. The usual dosage should be referred to the package insert for complete information. The tablets should be stored at controlled room temperature between 59°F and 86°F with excursions permitted between 15°C and 30°C. It is advised not to use the medication if the printed inner seal of the bottle is broken or missing. Dispensed by pharmacists, the medication is manufactured by Sandoz Private Ltd, India. Each bottle contains 30 tablets and is intended for patients as per the accompanying Medication Guide. The revision date for this information is March 2026.*
FDA Label Image

5mgx30tablets (5 mgx30tablets)

5mgx30tablets (5 mgx30tablets)
This text provides details about a medication called dapagliflozin containing 5 mg per film-coated tablet. It also mentions storage instructions and precautions. The medication is manufactured by Sandoz Private Ltd. The text advises pharmacists to dispense the medication and includes information on the product originating from India.*
FDA Label Image

Chemicalstructure (Chemicalstructure)

Chemicalstructure (Chemicalstructure)
FDA Label Image

Figure-dapagliflozin-02 (Figure Dapagliflozin 02)

Figure-dapagliflozin-02 (Figure Dapagliflozin 02)
FDA Label Image

Figure-dapagliflozin-03 (Figure Dapagliflozin 03)

Figure-dapagliflozin-03 (Figure Dapagliflozin 03)
This is a description of a study evaluating the adjusted mean change in HbA1c over time for two groups: one receiving a placebo plus metformin, and the other receiving dapagliflozin 10 mg plus metformin. The data is presented in two graphs showing the changes at different study weeks. The study includes subjects who completed a short-term period with both baseline and Week 24 HbA1c values without rescue interventions. The graphs display values based on longitudinal repeated measures and ANCOVA models, along with confidence intervals.*
FDA Label Image

Figure-dapagliflozin-04 (Figure Dapagliflozin 04)

Figure-dapagliflozin-04 (Figure Dapagliflozin 04)
This description provides data on the number of patients in the study receiving Dapagliflozin and Placebo, the timeline in months from randomization, and the number of patients at risk at various time points.*
FDA Label Image

Figure-dapagliflozin-05 (Figure Dapagliflozin 05)

Figure-dapagliflozin-05 (Figure Dapagliflozin 05)
The data provided shows the comparison between Dapagliflozin and Placebo over a period of 60 months. It includes information on the number of patients at risk for each treatment group at different time points. The number of patients at risk decreases gradually over time for both Dapagliflozin and Placebo groups. This data can be used to analyze the effectiveness and outcomes of the two treatments over the specified time period.*
FDA Label Image

Figure-dapagliflozin-01 (Dapagliflozin 01)

Figure-dapagliflozin-01 (Dapagliflozin 01)
This is a record of levels of CFB in 24-hour urinary glucose (g) along with observed values for healthy subjects and subjects with T2DM. The table includes data on Dapagliflozin dosage (mg) and depicts fitted lines for both healthy subjects and those with T2DM, showing differences in the levels detected in the two groups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.